AbstractTo the Editor: In our article we found that the prevalence of eosinophilia in our cohort of ART (antiretroviral therapy)-naïve patients infected with the human immunodeficiency virus (HIV) was 9.7%.1 This is slightly higher than similar rates reported in other studies performed in developed countries (Switzerland 6.3%,2 the Netherlands 6.3%,3 and the United States 5.5%4). Studies in developing countries showed much higher rates of eosinophilia in HIV-infected patients (Brazil 18%,5 Zimbabwe 23.5%,6 and Venezuela 28.2%7). In addition, a study in the United Kingdom by Sivaram et al demonstrated a rate of 19.5%; however, most of the patients in that study were from developed countries or had resided there for an extended period (58%).8
This content is limited to qualifying members.
If you have an existing account please login now to access this article or view your purchase options.
Create a free account, then purchase this article to download or access it online for 24 hours.
Create a free account, then purchase a subscription to get complete access to all articles for a full year.